Trial
NCT02426021
Phase 1 Single Subcutaneous Dose Study of MLN1202
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Healthy Japanese and Caucasian Male Adults
Intervention
MLN1202
Why stopped
Business decision; No Safety or Efficacy Concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-27